Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.

Thomas M AtkinsonJennifer L HaySoo Young KimElizabeth SchofieldMichael A PostowParisa MomtazAllison Betof WarnerAlexander N ShoushtariMargaret K CallahanJedd D WolchokYuelin LiPaul B Chapman

Published in: The oncologist (2023)

When provided with comprehensive quantitative information about risks and benefits of adjuvant anti-PD1 immunotherapy, 20/34 (59%) of patients opted for observation. Patients choosing adjuvant immunotherapy had lower decisional regret and higher satisfaction over time even if they had poorer outcomes in treatment.

Keyphrases

end stage renal disease
early stage
ejection fraction
newly diagnosed
chronic kidney disease
decision making
type diabetes
high resolution
insulin resistance
mass spectrometry
human health
glycemic control